论文部分内容阅读
本文报告以氟脲嘧啶(F)、阿霉素(A)、丝列霉素(M)联合化疗,治疗并随访10例晚期腺型癌肿,患者男性8例,女性2例,年龄为32～61岁。其中低分化4例,高分化及未分化各1例,腺型4例。沿用文献介绍的Ⅰ、Ⅱ、Ⅲ方案治疗,为保证能较久使用ADR,提高疗效,又另增方案Ⅳ(8周后间隙2月:MMC8～10mg,ADR30～40mg,均第1、9天,5Fu0.5g静滴,每周一次×8周,间隙2月后再重复用药),方案V(每8用一疗程:MMC10mg,AD R30mg,
This report reports the combination of 5-fluorouracil (F), Adriamycin (A), and Adriamycin (M) chemotherapy for the treatment and follow-up of 10 cases of advanced adenocarcinoma, 8 males and 2 females, age 32 ~ 61 years old. Among them, 4 cases were poorly differentiated, 1 case was well-differentiated and undifferentiated, and 4 cases were glandular. According to the I, II, and III regimens described in the literature, in order to ensure long-term use of ADR and improve efficacy, another regimen IV (8 months after the gap: MMC 8 to 10 mg, ADR 30 to 40 mg, both on days 1 and 9) , 5Fu 0.5g intravenous infusion, once a week × 8 weeks, repeated medication after 2 months interval), protocol V (every 8 treatment course: MMC 10mg, AD R30mg,